Physician profile
John Downs
NPI 1093780496
$713.80
in general payments reported to CMS, 2019-2025
19 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $22.67 · 2021: $79.65 · 2023: $15.00 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $131.82 | 2019-2025 | Talvey |
| Novartis Pharmaceuticals Corporation | $96.00 | 2019 | |
| Genentech USA, INC. | $57.96 | 2019-2021 | |
| Pfizer INC. | $51.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $50.12 | 2019-2021 | |
| Foundation Medicine, INC. | $43.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.90 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $34.62 | 2019 | |
| Merck Sharp & Dohme LLC | $30.38 | 2025 | Keytruda |
| Celgene Corporation | $29.35 | 2019 | |
| Daiichi Sankyo INC. | $23.22 | 2025 | Datroway |
| Abbvie INC. | $21.26 | 2019 | |
| Amgen INC. | $19.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.22 | 2019 | |
| Lilly USA, LLC | $15.11 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $15.00 | 2023 | Krazati |
| Tesaro, INC. | $14.07 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.78 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.